Tumour-Agnostic Efficacy and Safety of Selpercatinib in Patients With RET Fusion-Positive Solid Tumours Other Than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1/2, Open-Label, Basket Trial

Tumour-Agnostic Efficacy and Safety of Selpercatinib in Patients With RET Fusion-Positive Solid Tumours Other Than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1/2, Open-Label, Basket Trial

header-info

Selpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications.